Regenerative Medicine and Stem Cells Technologies

Deputy for international affairs and technological exchange aimed to publish the book of Science and Technology in Iran: A Brief Review considering its mission in the field of international cooperation in science and technology with the aim of introducing some of the capabilities of technology with the approach of developing technology diplomacy.

Preclinical studies suggest that bb2121, a chimeric antigen receptor (CAR) T-cell therapy that targets B-cell maturation antigen (BCMA), has potential for the treatment of multiple myeloma.

A new study released this week in STEM CELLS Translational Medicine (SCTM) offers hope for anyone who has suffered a serious corneal injury that did not respond well to conventional treatment.

Researchers at St. Jude Childrens Research Hospital have discovered how two proteins interact to control hundreds of genes that build the developing human brain.

Gratifying progress has been made recently in an emerging area of cancer medicine called precision oncology. It’s a bold attempt to target treatment to the very genes and molecules driving a cancer, aiming to slow or even halt its growth.

Induced pluripotent stem cells, the workhorse of many regenerative medicine projects, start out as differentiated cells that are reprogrammed to pluripotent stem cells by exposure to a complex set of genetic cocktails

Cell membrane re-engineering is emerging as a powerful tool for the development of next generation cell therapies, as it allows scientists to provide additional functions in the therapeutic cells, such as homing, adhesion or hypoxia (low oxygen) resistance.

Novo Nordisk A/S, the maker of diabetes drugs grappling with U.S. pricing pressure, said it’s considering entering the fast-growing gene therapy field through potential partnerships.

A study led by the UPV/EHU has developed an innovative, simple treatment based on uterine stem cells to combat the Candida albicans fungus, responsible for vaginal candidiasis.

The transformation of embryonic stem cells, and their induced pluripotent counterparts into potentially limitless supplies of new heart tissue has been hindered by a lack of consistency from one stem cell line to the next, as well as a poor understanding of the differentiation process.